For research use only. We do not sell to patients.
Ionizable lipids / Lipid 1A7B13
Lipid 1A7B13 chemical structure
Product imageResearch use only
CAT. NO. DC68023Featured

Lipid 1A7B13

Pack size & price

USD
TotalUS$600
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

Lipid 1A7B13 is a permanently cationic LuT lipid investigated as a lung-targeting component in multicomponent LNPs. The published study reports pulmonary mRNA delivery, cell-type-resolved reporter activity, gene-editing outcomes and acute tolerability in mice.

Open full Formulation & Performance →

Literature evidence · DC68023

Formulation & Performance

1A7B13 is the permanently charged lung-targeting component of a five-lipid formulation. Results are separated by reporter, cell population and assay; the high Cre reporter percentages are not presented as endogenous genome-editing rates.

The catalog uses the 1:1 bromide salt identity, C65H130BrNO4, molecular weight 1069.66. This is a catalog calculation basis, not a batch counterion assay. The ionizable companion lipid in the cited LNP is 4A3-SC7, not 4A3-SC8.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
4A3-SC7DC608551411.0711.90.167917
DOPEDC33634744.0311.90.088540
CholesterolDCD-041386.6523.820.092100
DMG-PEG2000DC4016925072.380.059667
Lipid 1A7B13DC680231069.66500.534830

Component order: 4A3-SC7/DOPE/cholesterol/DMG-PEG2000/1A7B13 = 11.90:11.90:23.82:2.38:50 mol%. The reported total lipid:mRNA mass ratio is 40:1. This is not 1A7B13:mRNA or N/P. The conversion uses the bromide-salt MW for 1A7B13 and 2507 for DMG-PEG2000.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
4A3-SC7——
DOPE——
Cholesterol——
DMG-PEG2000——
Lipid 1A7B13——

Formulation role and particle evidence

Study / conditionResultInterpretation
LuT componentPermanently cationic, at 50 mol% of the five-component LNPComplements the ionizable 4A3-SC7 component; not a one-component carrier.
Particle-size screenLibrary particles were predominantly approximately 100–150 nm with PDI <0.2Library-level range, not a lot specification for 1A7B13.
Mechanistic assaysEnhanced fusion/release in endosomal-mimic assays and altered protein-corona profilesMechanistic associations; not an in vivo escape percentage.

Main Figs. 2–5, Methods and Supplementary Fig. 18. Product conversion reflects the approved bromide salt.

Lung expression and cellular reporter delivery

Study / conditionResultInterpretation
Luciferase comparisons1A7B13 LNPs outperformed DOTAP LNPs across the tested dose-response seriesUse source curves rather than assigning the maximum library fold-change to this molecule.
Cre reporter; Ai14 mice; 0.3 mg mRNA/kg IV; 48 h93.7% pulmonary endothelial and 54.8% epithelial cells reporter-positivePercent of each gated population; not percent of all lung cells.
Lower-dose Cre experimentApproximately 49.57% epithelial reporter positivity at 0.05 mg/kgA separate dose experiment; not a genome-editing percentage.

Main Fig. 4 and Supplementary Figs. 27–31. Cre-dependent recombination and Cas9 editing are different assays.

Cas9 reporter editing: distinct from Cre delivery

Study / conditionResultInterpretation
Ai14 reporter study; two IV doses, 48 h apart; 0.75 mg total RNA/kg per dose26.5% reporter-positive total lung cells with 1A7B13 versus 6.2% with DOTAPAssessed 10 days after the second dose.
Cell-type analysisApproximately 73% endothelial, 34% epithelial and 16% immune cellsCorresponding DOTAP values were approximately 31%, 23% and 6%.
InterpretationFluorescent reporter activation demonstrates editing in this engineered locusDoes not establish equivalent editing at every endogenous target.

Main Fig. 6b–e.

Endogenous-target assay and interpretation

Study / conditionResultInterpretation
PTEN locus, total-lung DNA20.23% indels with 1A7B13 versus 2.20% with DOTAPSequencing-derived endpoint; not the Cre reporter percentage.
Study contextTwo 0.75 mg total RNA/kg IV doses; post-treatment genomic analysisPreclinical proof of delivery/editing, not a therapeutic recommendation.
ImmunostainingLoss of protein staining was measured separatelyProtein-negative cells and DNA indels are not interchangeable measures.

Main Fig. 6f–i. The study text and timeline should be consulted for the endpoint-specific assessment schedule.

Acute tolerability and translational limits

Study / conditionResultInterpretation
Luciferase mRNA LNP; 0.75 mg/kg IV; C57BL/6 mice; n = 3No overt lung histological injury in the reported 48 h assessmentAcute study with PBS and inflammatory positive controls.
Thrombosis comparisonNo observable clots in the tested 1A7B13-LNP group; DOTAP lipoplex control showed clotsThe control is a lipoplex formulation, not every possible DOTAP LNP.
Serum chemistryALT, AST, BUN and creatinine assessed at 24 and 48 h in supplementary studiesNo overt acute signal reported under those conditions.
Remaining evidence needsRepeat-dose tolerability, durability and larger-animal translationNot established by the reported acute mouse results.

Main Fig. 5i–j and Supplementary Figs. 37–39.

Original study figures

Lung expression and cell-type delivery — Figure 4 — Original source figures.

Mechanistic and acute tolerability data — Figure 5 — Original source figures.

Reporter and endogenous editing results — Figure 6 — Original source figures.

References and source locations

  1. Tian Z, Wang X, Chatterjee S et al. “Tripod-like” lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing. Nature Biomedical Engineering (2026). DOI: 10.1038/s41551-026-01615-9
CAS No.Not available
Chemical NameLipid 1A7B13
SynonymsLipid 1A7B13
SMILESCCCCCCCCCCCC[N+](C)(CCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC)CCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC.[Br-]
FormulaC65H130BrNO4
M.Wt1069.66
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Tian Z, Wang X, Chatterjee S et al. “Tripod-like” lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing. Nature Biomedical Engineering (2026). DOI: 10.1038/s41551-026-01615-9
F&PFormulation & PerformanceComposition, study results and referencesRead online →
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg9.3488 mL1.8698 mL0.9349 mL
25 mg23.3719 mL4.6744 mL2.3372 mL
50 mg46.7438 mL9.3488 mL4.6744 mL
100 mg93.4877 mL18.6975 mL9.3488 mL
250 mg233.7191 mL46.7438 mL23.3719 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.